Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-535P** (RNA, U6 small nuclear 535, pseudogene) is a non-coding RNA _pseudogene_ and not a protein-coding gene or canonical therapeutic target[3]. U6 small nuclear RNAs (snRNAs) typically participate in the splicing of pre-mRNA as essential components of the spliceosome, but **RNU6-535P** is a _pseudogene_, meaning it is a genomic sequence that resembles the functional U6 snRNA gene but has accumulated mutations that prevent it from producing a functional RNA product[4][3]. Pseudogenes are generally considered non-functional remnants of gene evolution, although some may be transcribed and could potentially participate in the regulation of other genes by serving as sources of small interfering RNAs or acting as miRNA decoys[6]. There is no specific evidence that RNU6-535P has such functions, nor is it associated with specific diseases or interacting drugs.\nRNU6-535P is one of many U6 snRNA pseudogenes found throughout the genome—this reflects the abundance and evolutionary conservation of the U6 snRNA sequence, which is itself essential for the splicing of pre-mRNA via the major spliceosome[5][3]. However, this specific pseudogene is not a _receptor_, _enzyme_, _transporter_, or any protein-based target.\n\nKey points:\n- **Not a protein, enzyme, receptor, or common drug target**\n- **Not known to have a direct role as a therapeutic, diagnostic, or prognostic biomarker**\n- **No known drug interactions or safety concerns**\n- Pseudogenes in general may have regulatory potential at the RNA level, though such roles remain largely unproven for most individual pseudogenes, including RNU6-535P[4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 535, pseudogene (RNU6-535P).